Findings from a phase three, randomized controlled clinical trial demonstrate the superiority of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) over autologous arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease (ESKD).

A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events, and inpatient admissions.

Findings from a comprehensive 20-year clinical study demonstrate treatment of functional popliteal artery entrapment syndrome (FPAES), particularly in combination with fasciotomy for exertional compartment syndrome, has shown highly effective outcomes, with 82% of patients returning to prior level of athletics.

According to a new national survey released by the Society for Vascular Surgery (SVS), primary care providers rank vascular disease among the top three health crises facing our aging population, only behind heart disease and cancer and ahead of obesity and diabetes.

Intermountain Health St. Mary’s Regional Hospital receives ACS/SVS Vascular Verification 

New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness

Get a Pulse on PAD: 70% of Americans Lack Awareness of Peripheral Artery Disease, with New Survey Underscoring Gaps in Awareness Among Most At-Risk Patients 

Underserved communities continue to struggle with health care disparities such as diabetes and peripheral arterial disease (PAD), which can lead to limb amputation.

Chicago, IL (November 1, 2023) – The Society for Vascular Surgery (SVS) is among 11 recipients of a $100,000 grant from the Council of Medical Specialty Societies (CMSS), aimed to promote diagnostic excellence across the field of medicine.